Search for a trial

A phase 3, multicenter, randomized, double-blind, placebo-controlled study of AG-881 in subjects with residual or recurrent grade 2 glioma with and IDH1 or IDH2 mutation

This study has been transitioned to CTIS with ID 2024-512961-15-00 check the CTIS register for the current data. Primary:• The primary objective of the study is to demonstrate the efficacy of vorasidenib based on radiographic progression-free…